Proposed reforms to the OTC derivatives market in the US could accelerate similar changes in Europe, but are unlikely to change radically the direction in which the continent was already travelling, industry participants and regulators said on Thursday.

“It wasn’t a surprise – and I think we’ll get to the same place in Europe, but possibly over a longer timeframe and in a more piecemeal fashion,” said one senior industry participant, involved in EU talks over regulatory reform.